Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daiken Biomedical Co., Ltd. (7780:TWSE), powered by AI.
Daiken Biomedical Co., Ltd. is currently trading at $185.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Daiken Biomedical Co., Ltd. on Alpha Lenz.
Daiken Biomedical Co., Ltd.'s P/E ratio is 76.2.
“Daiken Biomedical Co., Ltd. trades at a P/E of 76.2 (premium valuation) with solid ROE of 13.7%.”
Ask for details →Daiken Biomedical Co., Ltd. is a Taiwan-based company specializing in the research, development, and sales of health food and nutritional supplements. Established in 2018, the company delivers a wide array of products including fish oil soft capsules, lutein for eye health, maca supplements, bitter melon peptide cinnamon capsules, probiotics for women, sesamin for sleep, and dietary fiber powders. Daiken Biomedical emphasizes evidence-based product development, leveraging an international biomedical research team comprising experts from the United States, Japan, and Taiwan to ensure rigorous safety and efficacy standards. Its offerings are marketed primarily within Taiwan, both through online channels such as momo, Shopee, and PChome, and in physical retail outlets like Watsons and FamilyMart. The company plays a prominent role in Taiwan’s consumer defensive sector, serving the growing demand for lifestyle-oriented, scientifically substantiated health products. Daiken Biomedical is notable for integrating global research perspectives and maintaining direct relationships with end consumers, reflecting its commitment to both product quality and customer trust.
“Daiken Biomedical Co., Ltd. trades at a P/E of 76.2 (premium valuation) with solid ROE of 13.7%.”
Ask for details →Daiken Biomedical Co., Ltd. (ticker: 7780) is a company listed on TWSE in the Consumer Defensive sector (Packaged Foods). Market cap is $8.1B.
The current price is 185 with a P/E ratio of 76.16x and P/B of 6.21x.
ROE is 13.71% and operating margin is 11.00%. Annual revenue is $1.4B.